middle.news
Paradigm Biopharma Accelerates Phase 3 Trial Ahead of Mid-2026 Interim Analysis
8:24am on Friday 27th of February, 2026 AEDT
•
Biotechnology
Read Story
Paradigm Biopharma Accelerates Phase 3 Trial Ahead of Mid-2026 Interim Analysis
8:24am on Friday 27th of February, 2026 AEDT
Key Points
Net loss widens to A$23.24 million reflecting increased Phase 3 clinical investment
Global Phase 3 PARA_OA_012 trial progressing with 59 active sites across multiple countries
Mid-2026 interim analysis targeted as a major de-risking and commercial milestone
Acquisition of oral therapy IP broadens osteoarthritis treatment pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX:PAR)
OPEN ARTICLE